Glycosylated Peptide Market Analysis 2018-2026: Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis

New product launches by the key manufacturers are fueling growth of the glycosylated peptide market. For instance, in 2017, Pfizer Inc., received the U.S. Food and Drug Administration (FDA) approval for Ixifi (infliximab-qbtx), a chimeric human-murine monoclonal antibody, as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Furthermore, in Feb 2017, CT-P10 received approval from the European Commission and in June 2017, it was approved by U.S. FDA.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1576

Furthermore, Sumsung Bioepis’s Infliximab biosimilar candidate SB2 got Ministry of Food and Drug Safety approval for Korea in 2016, European Commission approval for Europe in 2016, Therapeutic Goods Administration (TGA) approval for Australia in 2016, US FDA approval in 2017 and Health Canada (HC) approval of Canada in 2017. Moreover, company received European Commission (EC), Ministry of Food and Drug Safety (MFDS) and TGA approval for its Adalimumab biosimilar, SB5 in 2017 and 2018. However, challenges associated with the biosimilar product approval and stringent regulatory policies are restraining growth of the glycosylated peptide market.

Increasing application of glycosylated peptide is expected to fuel growth of the glycosylated peptide market. For instance, in 2015, Sussex Research Laboratories Inc., a specialist in glycodesign and the synthesis of complex carbohydrates, announced successful clinical trials for Glycolastin, anti-aging glycopeptide cosmetic active. The in-vitro studies for comparing efficacy of Glycolastin against non-glycosylated peptide reported increased secretion of structural protein elastin, fibronectin, and collagens by fibroblast. Furthermore, company plans to commercialize Glycolastin, as a cosmetic active in topical anti-aging products.

Advantages offered by glycosylated peptide over conventional peptide drug are the key factor driving growth of the glycosylated peptide market. For instance, Amgen’s Aranesp is used for treatment of anemia associated with chronic renal failure (CRF), having 5 N-linked oligosaccharide chain, which has three fold longer half-life as compared to Epogen, a 3 N-linked oligosaccharide chain. Furthermore, product approvals, inorganic strategies by key players, and various application of glycosylated peptide are some of the factors driving growth of the glycosylated peptide market.

Major players operating in glycosylated peptide market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis, and Celltrion Inc.

Request Sample Copy Of This Report: www.coherentmarketinsights.com/insight/request-sample/1576

Glycosylated Peptide Market - Taxonomy

By Product

Monoclonal Antibodies (mAbs)
Erythropoietin (EPO)
Other Products
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.